Expert Insights: Optimal Approaches to the Treatment of Multiple Myeloma
Release Date: February 1, 2021
Expiration Date: February 1, 2022
Watch the experts who are actively engaged in the care of patients with multiple myeloma as they reinforce key points and highlight the most clinically relevant data presented during the symposium that preceded the 2020 ASH Annual Meeting & Exposition.
The target audience for this activity is community and academic medical oncologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with MM.
After participating in this activity, participants should be better able to:
- Evaluate clinical trial results of frontline treatment options that are available for the treatment of patients with newly diagnosed MM
- Review maintenance therapy strategies for patients with MM that are eligible to receive this type of therapy
- Assess treatment approaches and sequencing of therapy for patients with relapsed and/or refractory MM
- Optimize approaches to manage treatment-related adverse events that may occur during the treatment of patients with MM
- Discuss clinical trials results that are investigating emerging novel agents in patients with MM
In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Bio Ascend. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The University of Nebraska Medical Center designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Method of Participation
There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation.
Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.
As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planner and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.
This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.
The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.
All faculty and planning committee members have no conflicts to disclose with the exception of the following:
Sagar Lonial, MD, FACP
Chief Medical Officer
Winship Cancer Institute of Emory University
Professor and Chair, Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Emory University School of Medicine
Consulting Fees: Amgen Inc., Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline LLC, Janssen Oncology, Karyopharm Therapeutics, Merck & Co., Novartis
Pieter Sonneveld, MD
Department Head and Professor of Hematology
Erasmus MC Cancer Institute
University Medical Center Rotterdam
Rotterdam, Holland, Netherlands
Employment: Hematology, Erasmus MC Cancer Institute, Rotterdam
Discussion of off-label drug use: Not Applicable
Research support: Amgen, Celgene, Janssen, Karyopharm, SkylineDx
Advisory Boards: Amgen, BMS/Celgene, Janssen, Karyopharm, Oncopeptides, Skyline Dx, Seattle Genetics
Chair: European Myeloma Network
Chair: Hovon Myeloma Working Group
The following planning committee members have nothing to disclose:
Bio Ascend: Dru Dace, PhD; Chloe Dunnam; Kraig Steubing
UNMC: Brenda Ram, CMP, CHCP
This activity is supported by independent educational grants from GlaxoSmithKline, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC., and Oncopeptides.
Select the Continue button below to begin. You may return later if you are unable to complete the activity at this time.